🔎 Trials Near Me

Home › Urothelial (Transitional Cell) Carcinoma › California

Urothelial (Transitional Cell) Carcinoma clinical trials in California

33 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in California.

Cities in California

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #59, Santa Barbara
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06524544

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • City of Hope National Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
  • Ronald Reagan UCLA Medical Center, Los Angeles
  • and 3 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07090499

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  • Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07566156

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Keck Medicine of USC Koreatown, Los Angeles
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

  • Providence St. Johns Health Center, Santa Monica
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange
  • University of California San Francisco ( Site 1044), San Francisco
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05562830

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  • UCLA Hematology/Oncology - Alhambra, Alhambra
  • UCLA Hematology/Oncology - Atascadero, Atascadero
  • UCLA Hematology/Oncology - Beverly Hills, Beverly Hills
  • and 39 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • City of Hope Cancer Center-Duarte, Duarte
  • Providence Medical Foundation, Santa Rosa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Precision NextGen Oncology, Beverly Hills
  • OPN Healthcare, Inc, Glendale
  • University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
  • TRIO-US (Translational Research in Oncology-US), Los Angeles
  • UCLA Hematology/Oncology - Santa Monica, Los Angeles
  • and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UC San Diego Moores Cancer Center, La Jolla
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06439836

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

  • Research Site, Los Angeles
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07815665

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • City of Hope, Duarte
  • START - Los Angeles, Los Angeles
  • Cedars Sinai, Los Angeles
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

  • Michael G Oefelein Clinical Trials, Bakersfield
  • UC Irvine Health. Chao Family Comprehensive Cancer Center, Orange
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06774131

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • University of Southern California, Los Angeles
  • Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
  • Cedars-Sanai Medical Center, Los Angeles
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Community Cancer Institute, Clovis
  • USC/Norris Comprehensive Cancer Center, Los Angeles
  • Hoag Memorial Hospital Presbyterian, Newport Beach
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04895709

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Los Angeles Cancer Network, Los Angeles
  • Pih Health Hematology Medical Oncology, Whittier
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Glendale
  • California Research Institute, Los Angeles
  • and 3 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  • Research Site, San Francisco
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07720284

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • Kaiser Permanente Anaheim Kraemer Medical Offices, Anaheim
  • Foothill Cardioology, Arcadia
  • Kaiser Permanente Baldwin Park Medical Center, Baldwin Park
  • and 58 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT04879329

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  • USC Norris Comprehensive Cancer Center, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07169734

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

  • Urology Associates of Central California, Fresno
  • Urology Group of Southern California, Los Angeles
  • Comprehensive Urology, Los Angeles
Recruiting
Ages 18 to 88 · All sexes · Updated Jul 2, 2026 · NCT06394869

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

  • University of California, Davis, Sacramento
Recruiting
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06101290

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

  • City of Hope, Duarte
  • COH Lennar, Irvine
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07484022

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT06682728

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

  • University of Southern California, Los Angeles
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Duarte
  • Massive Bio SYNERGY-AI site, Irvine
  • Massive Bio SYNERGY-AI site, La Jolla
  • and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

  • University of Southern California, Los Angeles
  • University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

  • Sarcoma Oncology Center, Santa Monica
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 3, 2025 · NCT06493552

A Multicenter Cancer Biospecimen Collection Study

  • Curebase, San Francisco
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 12, 2025 · NCT04510129

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.